title: A polyamine-deficient diet opposes hyperalgesia, tolerance and the increased anxiety-like behaviour associated with heroin withdrawal in rats.
abstract: In humans, hyperalgesia, tolerance and anxiety disorders are common symptoms during heroin withdrawal syndrome. Significant evidence supports a role of NMDA receptors in these phenomena. Because polyamines may positively modulate the functioning of NMDA receptors and mainly originate from dietary intake, one hypothesis is that a polyamine deficient diet (PD diet) may reduce withdrawal symptoms. To address this question, we investigated the ability of a PD diet to prevent or to alleviate some symptoms of withdrawal syndrome as hyperalgesia, and increased anxiety-like behaviour in rats receiving 14 once daily subcutaneous heroin injections. Here, we show that a PD diet has both preventive and curative properties for reducing certain signs of withdrawal such as hyperalgesia, tolerance and increased anxiety-like behaviour observed in rats fed with a standard diet. Moreover, in heroin-withdrawn rats which were returned to basal pain sensitivity level, hyperalgesia following acute analgesia induced by a single heroin dose was observed in heroin-treated rats fed with standard diet, not in rats fed with a PD diet. Similarly, a stress-induced hyperalgesia induced by a non-nociceptive environmental stress session was observed in heroin-treated rats fed with standard diet. In contrast, a stress-induced analgesia was observed in heroin-treated rats fed with a PD diet, as it was observed in non heroin-treated rats. Since a PD diet for several weeks did not induce appreciable side-effects in rats, these preclinical results suggest that a PD diet could be an effective strategy for improving the relief of certain negative emotional states of heroin withdrawal syndrome and to allow reducing other medications generally used, such as opioid maintenance drugs.
authors.affiliation: Univ. Bordeaux, INCIA, UMR 5287, F-33000 Bordeaux, France.
authors.forename: Chloé
authors.initials: C
authors.lastname: Le Roy
authors.forename: Emilie
authors.initials: E
authors.lastname: Laboureyras
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Laulin
authors.forename: Guy
authors.initials: G
authors.lastname: Simonnet
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects / Q000494:pharmacology; D000818:Animals; D001007:Anxiety / Q000150:complications / Q000178:diet therapy*; D004032:Diet; D004195:Disease Models, Animal; D004361:Drug Tolerance; D003932:Heroin / Q000009:adverse effects* / Q000494:pharmacology; D006930:Hyperalgesia / Q000139:chemically induced / Q000150:complications / Q000178:diet therapy* / Q000517:prevention & control; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008570:Memory, Short-Term / Q000187:drug effects; D009043:Motor Activity / Q000187:drug effects; D010147:Pain Measurement; D011073:Polyamines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013375:Substance Withdrawal Syndrome / Q000150:complications / Q000178:diet therapy*
chemical_list: D000701:Analgesics, Opioid; D011073:Polyamines; D003932:Heroin